|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Podo F, Buydens LM, Degani H, Hilhorst R,
Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J,
Monleon D, et al: Triple-negative breast cancer: Present challenges
and new perspectives. Mol Oncol. 4:209–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Palucka K and Banchereau J:
Dendritic-cell-based therapeutic cancer vaccines. Immunity.
39:38–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sahin U and Tureci O: Personalized
vaccines for cancer immunotherapy. Science. 359:1355–1360. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
June CH, O'Connor RS, Kawalekar OU,
Ghassemi S and Milone MC: CAR T cell immunotherapy for human
cancer. Science. 359:1361–1365. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Postow MA, Chesney J, Pavlick AC, Robert
C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK,
Agarwala SS, et al: Nivolumab and ipilimumab versus ipilimumab in
untreated melanoma. N Engl J Med. 372:2006–2017. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Adams S, Gray RJ, Demaria S, Goldstein L,
Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, et
al: Prognostic value of tumor-infiltrating lymphocytes in
triple-negative breast cancers from two phase III randomized
adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin
Oncol. 32:2959–2966. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ali HR, Provenzano E, Dawson SJ, Blows FM,
Liu B, Shah M, Earl HM, Poole CJ, Hiller L, Dunn JA, et al:
Association between CD8+ T-cell infiltration and breast cancer
survival in 12,439 patients. Ann Oncol. 25:1536–1543. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Loi S, Michiels S, Salgado R, Sirtaine N,
Jose V, Fumagalli D, Kellokumpu-Lehtinen PL, Bono P, Kataja V,
Desmedt C, et al: Tumor infiltrating lymphocytes are prognostic in
triple negative breast cancer and predictive for trastuzumab
benefit in early breast cancer: Results from the FinHER trial. Ann
Oncol. 25:1544–1550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Emens LA: Breast cancer immunotherapy:
Facts and hopes. Clin Cancer Res. 24:511–520. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vonderheide RH, Domchek SM and Clark AS:
Immunotherapy for breast cancer: What are we missing? Clin Cancer
Res. 23:2640–2646. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nanda R, Chow LQ, Dees EC, Berger R, Gupta
S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al:
Pembrolizumab in patients with advanced triple-negative breast
cancer: Phase Ib KEYNOTE-012 study. J Clin Oncol. 34:2460–2467.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weiner HL, Huang H, Zagzag D, Boyce H,
Lichtenbaum R and Ziff EB: Consistent and selective expression of
the discoidin domain receptor-1 tyrosine kinase in human brain
tumors. Neurosurgery. 47:1400–1409. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jin H, Ham IH, Oh HJ, Bae CA, Lee D, Kim
YB, Son SY, Chwae YJ, Han SU, Brekken RA and Hur H: Inhibition of
discoidin domain receptor 1 prevents stroma-induced peritoneal
metastasis in gastric carcinoma. Mol Cancer Res. 16:1590–1600.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ambrogio C, Gómez-López G, Falcone M,
Vidal A, Nadal E, Crosetto N, Blasco RB, Fernández-Marcos PJ,
Sánchez-Céspedes M, Ren X, et al: Combined inhibition of DDR1 and
Notch signaling is a therapeutic strategy for KRAS-driven lung
adenocarcinoma. Nat Med. 22:270–277. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Heinzelmann-Schwarz VA, Gardiner-Garden M,
Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish
LH, Bali A, Kench JG, et al: Overexpression of the cell adhesion
molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian
epithelium and ovarian cancer. Clin Cancer Res. 10:4427–4436. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Park HS, Kim KR, Lee HJ, Choi HN, Kim DK,
Kim BT and Moon WS: Overexpression of discoidin domain receptor 1
increases the migration and invasion of hepatocellular carcinoma
cells in association with matrix metalloproteinase. Oncol Rep.
18:1435–1441. 2007.PubMed/NCBI
|
|
20
|
Yamanaka R, Arao T, Yajima N, Tsuchiya N,
Homma J, Tanaka R, Sano M, Oide A, Sekijima M and Nishio K:
Identification of expressed genes characterizing long-term survival
in malignant glioma patients. Oncogene. 25:5994–6002. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shen Q, Cicinnati VR, Zhang X, Iacob S,
Weber F, Sotiropoulos GC, Radtke A, Lu M, Paul A, Gerken G and
Beckebaum S: Role of microRNA-199a-5p and discoidin domain receptor
1 in human hepatocellular carcinoma invasion. Mol Cancer.
9:2272010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rudd ML, Mohamed H, Price JC, O'Hara AJ,
Le Gallo M, Urick ME; NISC Comparative Sequencing Program, ; Cruz
P, Zhang S, Hansen NF, et al: Mutational analysis of the tyrosine
kinome in serous and clear cell endometrial cancer uncovers rare
somatic mutations in TNK2 and DDR1. BMC Cancer. 14:8842014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Loriaux MM, Levine RL, Tyner JW, Fröhling
S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger
R, et al: High-throughput sequence analysis of the tyrosine kinome
in acute myeloid leukemia. Blood. 111:4788–4796. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ding L, Getz G, Wheeler DA, Mardis ER,
McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan
MB, et al: Somatic mutations affect key pathways in lung
adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Griffith OL, Spies NC, Anurag M, Griffith
M, Luo J, Tu D, Yeo B, Kunisaki J, Miller CA, Krysiak K, et al: The
prognostic effects of somatic mutations in ER-positive breast
cancer. Nat Commun. 9:34762018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Agnihotri S, Jalali S, Wilson MR, Danesh
A, Li M, Klironomos G, Krieger JR, Mansouri A, Khan O, Mamatjan Y,
et al: The genomic landscape of schwannoma. Nat Genet.
48:1339–1348. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Prykhozhij SV, Rajan V, Gaston D and
Berman JN: CRISPR multitargeter: A web tool to find common and
unique CRISPR single guide RNA targets in a set of similar
sequences. PLoS One. 10:e01193722015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
O'Brien A and Bailey TL: GT-Scan:
Identifying unique genomic targets. Bioinformatics. 30:2673–2675.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu L, Jensen H, Johnston JJ, Di Maria E,
Kloth K, Cristea I, Sapp JC, Darling TN, Huryn LA, Tranebjærg L, et
al: Recurrent, activating variants in the receptor tyrosine kinase
DDR2 cause warburg-cinotti syndrome. Am J Hum Genet. 103:976–983.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Klionsky DJ, Abdelmohsen K, Abe A, Abedin
MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD,
Adeli K, et al: Guidelines for the use and interpretation of assays
for monitoring autophagy (3rd edition). Autophagy. 12:1–222. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Grither WR and Longmore GD: Inhibition of
tumor-microenvironment interaction and tumor invasion by
small-molecule allosteric inhibitor of DDR2 extracellular domain.
Proc Natl Acad Sci USA. 115:E7786–E7794. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wherry EJ and Kurachi M: Molecular and
cellular insights into T cell exhaustion. Nat Rev Immunol.
15:486–499. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mori H, Kubo M, Kai M, Yamada M, Kurata K,
Kawaji H, Kaneshiro K, Osako T, Nishimura R, Arima N, et al:
T-bet+ lymphocytes infiltration as an independent better
prognostic indicator for triple-negative breast cancer. Breast
Cancer Res Treat. 176:569–577. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Alves F, Vogel W, Mossie K, Millauer B,
Höfler H and Ullrich A: Distinct structural characteristics of
discoidin I subfamily receptor tyrosine kinases and complementary
expression in human cancer. Oncogene. 10:609–618. 1995.PubMed/NCBI
|
|
38
|
Vogel W: Discoidin domain receptors:
Structural relations and functional implications. FASEB J. 13
(Suppl):S77–S82. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Leitinger B: Discoidin domain receptor
functions in physiological and pathological conditions. Int Rev
Cell Mol Biol. 310:39–87. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Canning P, Tan L, Chu K, Lee SW, Gray NS
and Bullock AN: Structural mechanisms determining inhibition of the
collagen receptor DDR1 by selective and multi-targeted type II
kinase inhibitors. J Mol Biol. 426:2457–2470. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gao H, Chakraborty G, Zhang Z, Akalay I,
Gadiya M, Gao Y, Sinha S, Hu J, Jiang C, Akram M, et al:
Multi-organ site metastatic reactivation mediated by non-canonical
discoidin domain receptor 1 signaling. Cell. 166:47–62. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yeung D, Chmielewski D, Mihai C and
Agarwal G: Oligomerization of DDR1 ECD affects receptor-ligand
binding. J Struct Biol. 183:495–500. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Leitinger B: Molecular analysis of
collagen binding by the human discoidin domain receptors, DDR1 and
DDR2. Identification of collagen binding sites in DDR2. J Biol
Chem. 278:16761–16769. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fu HL, Sohail A, Valiathan RR, Wasinski
BD, Kumarasiri M, Mahasenan KV, Bernardo MM, Tokmina-Roszyk D,
Fields GB, Mobashery S and Fridman R: Shedding of discoidin domain
receptor 1 by membrane-type matrix metalloproteinases. J Biol Chem.
288:12114–12129. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Carafoli F, Mayer MC, Shiraishi K, Pecheva
MA, Chan LY, Nan R, Leitinger B and Hohenester E: Structure of the
discoidin domain receptor 1 extracellular region bound to an
inhibitory Fab fragment reveals features important for signaling.
Structure. 20:688–697. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu
JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis
of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Johnson JD, Edman JC and Rutter WJ: A
receptor tyrosine kinase found in breast carcinoma cells has an
extracellular discoidin I-like domain. Proc Natl Acad Sci USA.
90:5677–5681. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Di Marco E, Cutuli N, Guerra L, Cancedda R
and De Luca M: Molecular cloning of trkE, a novel trk-related
putative tyrosine kinase receptor isolated from normal human
keratinocytes and widely expressed by normal human tissues. J Biol
Chem. 268:24290–24295. 1993.PubMed/NCBI
|
|
49
|
Zerlin M, Julius MA and Goldfarb M: NEP: A
novel receptor-like tyrosine kinase expressed in proliferating
neuroepithelia. Oncogene. 8:2731–2739. 1993.PubMed/NCBI
|
|
50
|
Kiedzierska A, Smietana K, Czepczynska H
and Otlewski J: Structural similarities and functional diversity of
eukaryotic discoidin-like domains. Biochim Biophys Acta.
1774:1069–1078. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yuge R, Kitadai Y, Takigawa H, Naito T,
Oue N, Yasui W, Tanaka S and Chayama K: Silencing of discoidin
domain receptor-1 (DDR1) concurrently inhibits multiple steps of
metastasis cascade in gastric cancer. Transl Oncol. 11:575–584.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Vogel WF, Aszodi A, Alves F and Pawson T:
Discoidin domain receptor 1 tyrosine kinase has an essential role
in mammary gland development. Mol Cell Biol. 21:2906–2917. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Takai K, Drain AP, Lawson DA, Littlepage
LE, Karpuj M, Kessenbrock K, Le A, Inoue K, Weaver VM and Werb Z:
Discoidin domain receptor 1 (DDR1) ablation promotes tissue
fibrosis and hypoxia to induce aggressive basal-like breast
cancers. Genes Dev. 32:244–257. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kim HG, Hwang SY, Aaronson SA, Mandinova A
and Lee SW: DDR1 receptor tyrosine kinase promotes prosurvival
pathway through Notch1 activation. J Biol Chem. 286:17672–17681.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kuijk LM, Verstege MI, Rekers NV, Bruijns
SC, Hooijberg E, Roep BO, de Gruijl TD, van Kooyk Y and Unger WW:
Notch controls generation and function of human effector CD8+ T
cells. Blood. 121:2638–2646. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Cho OH, Shin HM, Miele L, Golde TE, Fauq
A, Minter LM and Osborne BA: Notch regulates cytolytic effector
function in CD8+ T cells. J Immunol. 182:3380–3389. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yu W, Wang Y and Guo P: Notch signaling
pathway dampens tumor-infiltrating CD8+ T cells activity
in patients with colorectal carcinoma. Biomed Pharmacother.
97:535–542. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Juskaite V, Corcoran DS and Leitinger B:
Collagen induces activation of DDR1 through lateral dimer
association and phosphorylation between dimers. Elife. 6(pii):
e257162017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Bono F, De Smet F, Herbert C, De Bock K,
Georgiadou M, Fons P, Tjwa M, Alcouffe C, Ny A, Bianciotto M, et
al: Inhibition of tumor angiogenesis and growth by a small-molecule
multi-FGF receptor blocker with allosteric properties. Cancer Cell.
23:477–488. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Herbert C, Schieborr U, Saxena K, Juraszek
J, De Smet F, Alcouffe C, Bianciotto M, Saladino G, Sibrac D,
Kudlinzki D, et al: Molecular mechanism of SSR128129E, an
extracellularly acting, small-molecule, allosteric inhibitor of FGF
receptor signaling. Cancer Cell. 23:489–501. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tu MM, Lee FYF, Jones RT, Kimball AK,
Saravia E, Graziano RF, Coleman B, Menard K, Yan J, Michaud E, et
al: Targeting DDR2 enhances tumor response to anti-PD-1
immunotherapy. Sci Adv. 5:eaav24372019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Tao Y, Wang R, Lai Q, Wu M, Wang Y, Jiang
X, Zeng L, Zhou S, Li Z, Yang T, et al: Targeting of DDR1 with
antibody-drug conjugates has antitumor effects in a mouse model of
colon carcinoma. Mol Oncol. May 22–2019.(Epub ahead of print).
View Article : Google Scholar
|
|
63
|
Vehlow A, Klapproth E, Jin S, Hannen R,
Hauswald M, Bartsch JW, Nimsky C, Temme A, Leitinger B and Cordes
N: Interaction of discoidin domain receptor 1 with a
14-3-3-Beclin-1-Akt1 complex modulates glioblastoma therapy
sensitivity. Cell Rep. 26:3672–3683.e7. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Aguilera KY, Huang H, Du W, Hagopian MM,
Wang Z, Hinz S, Hwang TH, Wang H, Fleming JB, Castrillon DH, et al:
Inhibition of discoidin domain receptor 1 reduces collagen-mediated
tumorigenicity in pancreatic ductal adenocarcinoma. Mol Cancer
Ther. 16:2473–2485. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lu QP, Chen WD, Peng JR, Xu YD, Cai Q,
Feng GK, Ding K, Zhu XF and Guan Z: Antitumor activity of 7RH, a
discoidin domain receptor 1 inhibitor, alone or in combination with
dasatinib exhibits antitumor effects in nasopharyngeal carcinoma
cells. Oncol Lett. 12:3598–3608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Shitomi Y, Thogersen IB, Ito N, Leitinger
B, Enghild JJ and Itoh Y: ADAM10 controls collagen signaling and
cell migration on collagen by shedding the ectodomain of discoidin
domain receptor 1 (DDR1). Mol Biol Cell. 26:659–673. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Gao M, Duan L, Luo J, Zhang L, Lu X, Zhang
Y, Zhang Z, Tu Z, Xu Y, Ren X and Ding K: Discovery and
optimization of
3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel
selective and orally bioavailable discoidin domain receptor 1
(DDR1) inhibitors. J Med Chem. 56:3281–3295. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Ali-Rahmani F, FitzGerald DJ, Martin S,
Patel P, Prunotto M, Ormanoglu P, Thomas C and Pastan I: Anticancer
effects of mesothelin-targeted immunotoxin therapy are regulated by
tyrosine kinase DDR1. Cancer Res. 76:1560–1568. 2016. View Article : Google Scholar : PubMed/NCBI
|
